Paul Maier

Paul Victor Maier is currently Director at Ambrx, Inc. since 2022.
He is Independent Director at International Stem Cell Corp.
since 2007, Independent Director at Eton Pharmaceuticals, Inc. since 2017, Independent Director at Ambrx Biopharma Cayman, Inc. since 2022, and Executive Partner at Mason School of Business of The College of William & Mary.
Former positions include Chairman at Lackey Clinic; Independent Director at PURE Bioscience, Inc. (2012);.
Independent Director at Apricus Biosciences, Inc. (2012–2019); Director at Telik, Inc.; Independent Director at MabVax Therapeutics, Inc. (2014–2018); Independent Director at Ritter Pharmaceuticals, Inc.; Director at Talon Therapeutics, Inc. (2008–2011); Director at MabVax Therapeutics Holdings, Inc. (2014–2018); Independent Director at Ambrx Biopharma Cayman, Inc. (2023–2024); Director at Biological Dynamics, Inc.; Independent Non-Executive Director at Small Pharma, Inc.; Independent Non-Executive Director at 4D Pharma Plc (2021–2023); Treasurer & Vice President at Bausch Health Americas, Inc. (1990); Chief Financial Officer & Senior Vice President at Ligand Pharmaceuticals, Inc. (1992–2007); Chief Financial Officer at Sequenom, Inc. (2009–2014); Vice President-Finance at SPI Pharmaceuticals, Inc. (1984–1988); VP-DFW West Finance at DFS Group LP (Hawaii) (1990–1992); Vice President-Finance at DFS West (1990–1992).
Education includes undergraduate degree from The Pennsylvania State University in 1969 and an MBA from Harvard Business School.